Browsing Tag
semaglutide
42 posts
OrsoBio unveils ADA 2025 preclinical data showcasing dual-pathway obesity drug strategy with lean mass preservation
OrsoBio presents ADA 2025 data on TLC-6740 and TLC-1180 showing sustained fat loss and lean mass preservation in obesity models. Human trials underway.
How Novo Nordisk is building a post-semaglutide strategy: Inside its metabolic pipeline and innovation bets
Novo Nordisk pivots beyond semaglutide with amycretin, CagriSema, and oral GLP-1 therapies. See how it’s building its next-generation obesity drug platform.
How are GLP-1 drugs like Wegovy and Zepbound reshaping obesity care beyond weight loss in 2025?
GLP-1 drugs like Wegovy and Zepbound are reshaping obesity care in 2025, with benefits extending to cardiovascular, liver, and kidney health. Learn more now.
Semaglutide shows significant vascular benefits in PAD patients with type 2 diabetes, STRIDE trial confirms
Semaglutide improves walking capacity and reduces disease progression in PAD patients with type 2 diabetes, STRIDE trial results reveal at ADA 2025.
Gan & Lee Pharmaceuticals reveals competitive Phase 2 results for bofanglutide and GZR4 at ADA 2025 sessions
Gan & Lee Pharmaceuticals presented strong Phase 2 results for bofanglutide and GZR4 in type 2 diabetes, advancing its long-acting diabetes pipeline.
Novo Nordisk’s high-dose Wegovy delivers 21% weight loss in STEP UP Phase 3 trial results
Novo Nordisk’s high-dose Wegovy led to 21% weight loss in a Phase 3 trial. Learn what the STEP UP data means for obesity care and future regulatory plans.
The oral biologics revolution: How macrocyclic peptides could reshape drug delivery
Macrocyclic peptides are revolutionizing oral biologics. Explore how Merck, Protagonist, and others are turning injectables into convenient, high-impact pills.
Hims & Hers Health soars over 10% after Wegovy rollout, Q1 strength, and analyst upgrades
Hims & Hers Health stock jumped 10.36% on May 16, 2025, after a Wegovy rollout, strong Q1 earnings, and analyst upgrades boosted investor confidence.
Novo Nordisk’s CagriSema demonstrates superior weight loss results in REDEFINE 1 trial
Novo Nordisk A/S has unveiled significant findings from its REDEFINE 1 trial, marking a major advancement in the…
Biocon and Biomm ink exclusive deal to bring Semaglutide to Brazil
Biocon Limited (BSE code: 532523, NSE: BIOCON), a leader in global biopharmaceutical innovations, has announced a pivotal licensing…